Author: Qiu, Yingshan; Lam, Jenny K. W.; Leung, Susan W. S.; Liang, Wanling
Title: Delivery of RNAi Therapeutics to the Airways—From Bench to Bedside Document date: 2016_9_20
ID: 04pp3lv0_65
Snippet: RNAi targeting the essential inflammatory mediators could offer protection against the progression of the disease. In an in vivo study, systemic delivery of siRNA targeting TNF-α significantly reduced the expression of TNF-α in the lungs and lung injury in a shock-induced ALI mouse model [175] . The findings suggested that pulmonary vascular cells, but not the epithelial cells, contribute to the release of TNF-α leading to lung injury followin.....
Document: RNAi targeting the essential inflammatory mediators could offer protection against the progression of the disease. In an in vivo study, systemic delivery of siRNA targeting TNF-α significantly reduced the expression of TNF-α in the lungs and lung injury in a shock-induced ALI mouse model [175] . The findings suggested that pulmonary vascular cells, but not the epithelial cells, contribute to the release of TNF-α leading to lung injury following a systemic inflammatory insult. Although these findings are contradictory to the others who suggest that pulmonary epithelial cells are the major players for causing lung injury induced by a systemic disease [215, 216] , nevertheless, they provide evidence that support the use of siRNA targeting TNF-α in the management of ALI.
Search related documents:
Co phrase search for related documents- ALI management and mouse model: 1
- ALI mouse model and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- ALI mouse model and lung injury lung: 1, 2, 3, 4, 5
- ALI mouse model and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26
- ALI mouse model and TNF α expression: 1
- disease progression and epithelial cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- disease progression and inflammatory mediator: 1
- disease progression and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
- disease progression and lung injury lead: 1, 2, 3
- disease progression and lung injury lung: 1, 2, 3, 4, 5, 6
- disease progression and major player: 1, 2
- disease progression and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39
- disease progression and pulmonary epithelial cell: 1
- disease progression and systemic delivery: 1, 2, 3, 4, 5
- disease progression and systemic disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57
- disease progression and TNF α expression: 1, 2, 3, 4, 5, 6, 7, 8
- disease progression and vascular cell: 1, 2, 3, 4, 5, 6, 7, 8, 9
- disease progression and vivo study: 1, 2, 3, 4, 5, 6
- disease progression protection and lung injury: 1
Co phrase search for related documents, hyperlinks ordered by date